Effects of PCV7 and PCV13 on invasive pneumococcal disease and carriage in Stockholm, Sweden

European Respiratory Journal

Volumn 47, Issue 4, 2016, Pages 1208-1218

  Galanis, Ilias ^a   Lindstrand, Ann ^a,b   Darenberg, Jessica ^a   Browall, Sarah ^b,c   Nannapaneni, Priyanka ^b   Sjöström, Karin ^a   Morfeldt, Eva ^a   Naucler, Pontus ^b,c   Blennow, Margareta ^b,d   Örtqvist, Ake ^b   Henriques Normark, Birgitta ^a,b,c  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d SACHS CHILDREN S HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; PENICILLIN G; PNEUMOCOCCUS VACCINE; 13-VALENT PNEUMOCOCCAL VACCINE; VACCINE;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL PNEUMONIA; BACTERIAL STRAIN; BACTERIUM CARRIER; BACTERIUM ISOLATE; CHILD; CHILD HEALTH CARE; DISEASE SEVERITY; DRUG EFFECT; HERD IMMUNITY; HUMAN; HUMAN CELL; IMMUNIZATION; INCIDENCE; MAJOR CLINICAL STUDY; MENINGITIS; MICROBIAL DIVERSITY; MOLECULAR TYPING; NONHUMAN; PNEUMOCOCCAL INFECTION; PRESCHOOL CHILD; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHINOSINUSITIS; SEPTICEMIA; SEROTYPE; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; SWEDEN; ADOLESCENT; CLASSIFICATION; INFANT; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; NEWBORN; PNEUMOCOCCAL INFECTIONS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINE; HUMANS; IMMUNITY, HERD; INCIDENCE; INFANT; INFANT, NEWBORN; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MOLECULAR TYPING; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; SWEDEN; VACCINES, CONJUGATE; YOUNG ADULT;

EID: 84962927779     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.01451-2015     Document Type: Article

References (38)

1. Kalin M, Ortqvist A, Almela M, et al. Prospective study of prognostic factors in community-acquired bacteremic pneumococcal disease in 5 countries. J Infect Dis 2000; 182: 840-847.
2. O'Brien KL, Wolfson LJ, Watt JP, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009; 374: 893-902.
3. Pereira JM, Basílio C, Sousa-Dias C, et al. Can we predict pneumococcal bacteremia in patients with severe community-acquired pneumonia? J Crit Care 2013; 28: 970-974.
4. Koedel U, Scheld WM, Pfister HW. Pathogenesis and pathophysiology of pneumococcal meningitis. Lancet Infect Dis 2002; 2: 721-736.
5. Stockmann C, Ampofo K, Byington CL, et al. Pneumococcal meningitis in children: epidemiology, serotypes, and outcomes from 1997-2010 in Utah. Pediatrics 2013; 132: 421-428.
6. Henriques-Normark B, Tuomanen EI. The pneumococcus: epidemiology, microbiology, and pathogenesis. Cold Spring Harb Perspect Med 2013; 3: a010215.
7. McCullers JA, McAuley JL, Browall S, et al. Influenza enhances susceptibility to natural acquisition of and disease due to Streptococcus pneumoniae in ferrets. J Infect Dis 2010; 202: 1287-1295.
8. Klugman KP, Madhi SA. Pneumococcal vaccines and flu preparedness. Science 2007; 316: 49-50.
9. Sandgren A, Sjostrom K, Olsson-Liljequist B, et al. Effect of clonal and serotype-specific properties on the invasive capacity of Streptococcus pneumoniae. J Infect Dis 2004; 189: 785-796.
10. Sjostrom K, Spindler C, Ortqvist A, et al. Clonal and capsular types decide whether pneumococci will act as a primary or opportunistic pathogen. Clin Infect Dis 2006; 42: 451-459.
11. Bentley SD, Aanensen DM, Mavroidi A, et al. Genetic analysis of the capsular biosynthetic locus from all 90 pneumococcal serotypes. PLoS Genet 2006; 2: e31.
12. Bratcher PE, Kim KH, Kang JH, et al. Identification of natural pneumococcal isolates expressing serotype 6D by genetic, biochemical and serological characterization. Microbiology 2010; 156: 555-560.
13. Calix JJ, Porambo RJ, Brady AM, et al. Biochemical, genetic, and serological characterization of two capsule subtypes among Streptococcus pneumoniae serotype 20 strains: discovery of a new pneumococcal serotype. J Biol Chem 2012; 287: 27885-27894.
14. Henrichsen J. Six newly recognized types of Streptococcus pneumoniae. J Clin Microbiol 1995; 33: 2759-2762.
15. Ko KS, Baek JY, Song JH. Capsular gene sequences and genotypes of "serotype 6E" Streptococcus pneumoniae isolates. J Clin Microbiol 2013; 51: 3395-3399.
16. Oliver MB, van der Linden MP, Küntzel SA, et al. Discovery of Streptococcus pneumoniae serotype 6 variants with glycosyltransferases synthesizing two differing repeating units. J Biol Chem 2013; 288: 25976-25985.
17. Park IH, Pritchard DG, Cartee R, et al. Discovery of a new capsular serotype (6C) within serogroup 6 of Streptococcus pneumoniae. J Clin Microbiol 2007; 45: 1225-1233.
18. Zartler ER, Porambo RJ, Anderson CL, et al. Structure of the capsular polysaccharide of pneumococcal serotype 11A reveals a novel acetylglycerol that is the structural basis for 11A subtypes. J Biol Chem 2009; 284: 7318-7329.
19. Lin FL, Vinogradov E, Deng C, et al. Structure elucidation of capsular polysaccharides from Streptococcus pneumoniae serotype 33C, 33D, and revised structure of serotype 33B. Carbohydr Res 2014; 383: 97-104.
20. Fitzwater SP, Chandran A, Santosham M, et al. The worldwide impact of the seven-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2012; 31: 501-508.
21. Sharma D, Baughman W, Holst A, et al. Pneumococcal carriage and invasive disease in children before introduction of the 13-valent conjugate vaccine: comparison with the era before 7-valent conjugate vaccine. Pediatr Infect Dis J 2013; 32: e45-e53.
22. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003; 348: 1737-1746.
23. Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010; 201: 32-41.
24. Moore MR, Link-Gelles R, Schaffner W, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis 2015; 15: 301-309.
25. Moore MR, Gertz RE Jr, Woodbury RL, et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J Infect Dis 2008; 197: 1016-1027.
26. Simoes AS, Pereira L, Nunes S, et al. Clonal evolution leading to maintenance of antibiotic resistance rates among colonizing pneumococci in the PCV7 era in Portugal. J Clin Microbiol 2011; 49: 2810-2817.
27. Harboe ZB, Dalby T, Weinberger DM, et al. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clin Infect Dis 2014; 59: 1066-1073.
28. Steens A, Bergsaker MA, Aaberge IS, et al. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway. Vaccine 2013; 31: 6232-6238.
29. Waight PA, Andrews NJ, Ladhani SN, et al. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis 2015; 15: 535-543.
30. Henriqus Normark B, Christensson B, Sandgren A, et al. Clonal analysis of Streptococcus pneumoniae nonsusceptible to penicillin at day-care centers with index cases, in a region with low incidence of resistance: emergence of an invasive type 35B clone among carriers. Microb Drug Resist 2003; 9: 337-344.
31. Hermans PW, Sluijter M, Hoogenboezem T, et al. Comparative study of five different DNA fingerprint techniques for molecular typing of Streptococcus pneumoniae strains. J Clin Microbiol 1995; 33: 1606-1612.
32. Enright MC, Spratt BG. A multilocus sequence typing scheme for Streptococcus pneumoniae: identification of clones associated with serious invasive disease. Microbiology 1998; 144: 3049-3060.
33. Olsson-Liljequist B, Larsson P, Walder M, et al. Antimicrobial susceptibility testing in Sweden. III. Methodology for susceptibility testing. Scand J Infect Dis Suppl 1997; 105: 13-23.
34. Lindstrand A, Bennet R, Galanis I, et al. Sinusitis and pneumonia hospitalization after introduction of pneumococcal conjugate vaccine. Pediatrics 2014; 134: e1528-e1536.
35. Henriques B, Kalin M, Ortqvist A, et al. Molecular epidemiology of Streptococcus pneumoniae causing invasive disease in 5 countries. J Infect Dis 2000; 182: 833-839.
36. Kaplan SL, Barson WJ, Lin PL, et al. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2013; 32: 203-207.
37. Darenberg J, Henriques Normark B. The epidemiology of pneumococcal infections-The Swedish experience. Vaccine 2009; 27: Suppl. 6, G27-G32.
38. Paterson S, Vogwill T, Buckling A, et al. Antagonistic coevolution accelerates molecular evolution. Nature 2010; 464: 275-278.